Extension study of TEV-56286 for multiple system atrophy
Part of Brain & nervous system clinical trials.
This trial tests whether the drug TEV-56286 continues to work for multiple system atrophy (a rare brain disorder). It is for people who already completed a previous study of the same drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed a previous study (called TV56286-NDG-20039) and attended the week 48 visit.
- If you are a woman who could become pregnant, you must have a negative pregnancy test at the start.
- Women who could become pregnant and their male partners (if fertile) must use highly effective birth control during the study and for 28 days after the last dose.
- Men who are fertile and their female partners must use highly effective birth control during the study and for 28 days after the last dose.
- You cannot be pregnant, planning to become pregnant, or breastfeeding.
- You cannot be in a vulnerable population (like being in detention or jail).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TEV-56286 for people with Multiple System Atrophy (MSA), a rare brain disorder. It aims to see if the drug can help control symptoms and slow the disease.
This study tests a new antibody drug that targets a protein linked to multiple system atrophy (MSA). It aims to see if the drug is safe and may slow the disease, for people recently diagnosed.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
This study is collecting information from patients with multiple system atrophy (a rare neurological condition affecting movement and body functions), Parkinson disease, and healthy volunteers to better understand these conditions. By participating, you help doctors learn more about how these diseases develop and progress.
This trial tests whether a medication called butylphthalide can help slow or improve symptoms of multiple system atrophy (MSA), a rare neurological condition that affects movement, balance, and automatic body functions. The study will measure how well the drug works and how safe it is for patients.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.